UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 29, 2011

 

 

PSIVIDA CORP.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-51122   26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

400 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices) (Zip Code)

(617) 926-5000

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of pSivida Corp. (the “Company”) was held on November 29, 2011. The stockholders elected each of the Company’s nominees for director, approved the stock option grants to Dr. Ashton, approved the stock option grants to each of the Company’s non-executive directors and ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2012. The proposals below are described in detail in the Company’s definitive proxy statement filed with the SEC on October 25, 2011.

The results are as follows:

Proposal 1. Election of Directors.

 

DIRECTOR NOMINEE    FOR      WITHHELD      NON VOTES  

David J. Mazzo

     6,502,447         217,014         4,595,633   

Paul Ashton

     6,511,437         208,024         4,595,633   

Paul A. Hopper

     6,498,947         220,514         4,595,633   

Michael Rogers

     6,414,697         304,764         4,595,633   

Peter G. Savas

     5,117,354         1,602,107         4,595,633   

Proposal 2. Approval of stock option grants to CEO Paul Ashton.

 

FOR

     5,388,571   

AGAINST

     1,312,293   

ABSTAIN

     18,597   

NON VOTES

     4,595,633   

Proposal 3. Approval of stock option grant to non-executive directors.

 

DIRECTOR NOMINEE    FOR      AGAINST      ABSTAIN      NON VOTES  

Paul A. Hopper

     4,640,398         2,061,739         17,324         4,595,633   

Michael Rogers

     4,554,048         2,143,089         22,324         4,595,633   

Peter G. Savas

     4,228,227         2,061,589         429,645         4,595,633   

David J. Mazzo

     4,639,098         2,057,039         23,324         4,595,633   

Proposal 4. Ratification of the appointment of Deloitte & Touche LLP.

 

FOR

     10,654,268   

AGAINST

     642,873   

ABSTAIN

     17,953   


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PSIVIDA CORP.

Date: December 2, 2011   By:  

/s/ Lori Freedman

  Lori Freedman, Vice President, Corporate Affairs, General Counsel and Secretary